These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 24486109)

  • 21. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors.
    Saxena AK; Saxena S; Chaudhaery SS
    SAR QSAR Environ Res; 2010 Jan; 21(1):1-20. PubMed ID: 20373211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
    Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
    Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
    Zhao H; Garg G; Zhao J; Moroni E; Girgis A; Franco LS; Singh S; Colombo G; Blagg BS
    Eur J Med Chem; 2015 Jan; 89():442-66. PubMed ID: 25462258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
    Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
    Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis, and Evaluation of Heat Shock Protein 90 Inhibitors in Human Breast Cancer and Its Metastasis.
    Gümus M; Ozgur A; Tutar L; Disli A; Koca I; Tutar Y
    Curr Pharm Biotechnol; 2016; 17(14):1231-1245. PubMed ID: 27804852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designing, structural elucidation, comparison of DNA binding, cleavage, radical scavenging activity and anticancer activity of copper(I) complex with 5-dimethyl-2-phenyl-4-[(pyridin-2-ylmethylene)-amino]-1,2-dihydro-pyrazol-3-one Schiff base ligand.
    Sathiyaraj S; Sampath K; Butcher RJ; Pallepogu R; Jayabalakrishnan C
    Eur J Med Chem; 2013 Jun; 64():81-9. PubMed ID: 23644191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC).
    Jeong CH; Park HB; Jang WJ; Jung SH; Seo YH
    Bioorg Med Chem Lett; 2014 Jan; 24(1):224-7. PubMed ID: 24345447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening.
    Park H; Kim YJ; Hahn JS
    Bioorg Med Chem Lett; 2007 Nov; 17(22):6345-9. PubMed ID: 17869098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
    Abbasi M; Sadeghi-Aliabadi H; Amanlou M
    Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Lee KW
    Eur J Med Chem; 2011 Jul; 46(7):2937-47. PubMed ID: 21531051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90.
    Barta TE; Veal JM; Rice JW; Partridge JM; Fadden RP; Ma W; Jenks M; Geng L; Hanson GJ; Huang KH; Barabasz AF; Foley BE; Otto J; Hall SE
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3517-21. PubMed ID: 18511277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening.
    Abbasi M; Sadeghi-Aliabadi H; Hassanzadeh F; Amanlou M
    J Mol Graph Model; 2015 Sep; 61():186-95. PubMed ID: 26277488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity.
    Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Ingalls C; Sutherland AG; Sonye JP; Eid CN; Golas J; Liu H; Boschelli F; Hu Y; Vogan E; Levin JI
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2278-82. PubMed ID: 21420297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.
    Mettu A; Talla V; Bajaj DM; Subhashini NJP
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900063. PubMed ID: 31411362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and pharmacological evaluation of N-(5-chloro-2,4-dihydroxybenzoyl)-(R)-N-arylmethyl-1,2,3,4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors.
    Liang C; Wu X; Li Z; Zhu J; Lu C; Shen Y
    Eur J Med Chem; 2018 Jan; 143():85-96. PubMed ID: 29172085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N'-phenyl-thiourea.
    Zhang HJ; Qin X; Liu K; Zhu DD; Wang XM; Zhu HL
    Bioorg Med Chem; 2011 Sep; 19(18):5708-15. PubMed ID: 21872479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
    Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD
    Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibacterial Evaluation, In Silico Characters and Molecular Docking of Schiff Bases Derived from 5-aminopyrazoles.
    Hassan AS; Askar AA; Nossier ES; Naglah AM; Moustafa GO; Al-Omar MA
    Molecules; 2019 Aug; 24(17):. PubMed ID: 31466322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fe
    Maddela S; Makula A; Galigniana MD; Parambi DGT; Federicci F; Mazaira G; Hendawy OM; Dev S; Mathew GE; Mathew B
    Arch Pharm (Weinheim); 2019 Jan; 352(1):e1800174. PubMed ID: 30485473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.